177Lu-DOTATATE肽受体放射性核素治疗在表达生长抑素的神经内分泌肿瘤患者经区域肝栓塞后的安全性和有效性
该回顾性研究分析了143例接受177Lu-DOTATATE肽受体放射性核素治疗(PRRT)的表达生长抑素的神经内分泌肿瘤患者。有或无区域化疗栓塞和放射性核素肝栓塞(CRHE)病史的患者毒性比例相当(P=0.246),且任何毒性均与既往CRHE或栓塞至首次PRRT的间隔时间无统计学显著相关。CRHE患者PRRT后76.5%获得获益(部分缓解+疾病稳定),23.4%出现疾病进展;与无CRHE患者相比,CRHE患者疾病稳定更多(P=0.048)、疾病进展更少(P=0.046),两组获得部分缓解/完全缓解的概率相同(P=0.50)。结论认为既往CRHE病史并非后续PRRT的禁忌证。
要点
- 有或无CRHE病史患者PRRT后毒性比例相当(P=0.246)。
- CRHE患者PRRT后76.5%获得部分缓解+疾病稳定,23.4%出现疾病进展。
- CRHE患者较无CRHE者疾病稳定更多(P=0.048)、疾病进展更少(P=0.046)。
核心结论
- 177Lu-DOTATATE治疗在CRHE患者中未显示临床或统计学显著的毒性,与栓塞频率或栓塞至首次PRRT的间隔时间无关。
- 结果提示有CRHE病史的患者应答率在统计学上显著更高。
- 既往CRHE病史不是后续PRRT的禁忌证。
研究设计与样本
- 回顾性综述了143例接受177Lu-DOTATATE PRRT的表达生长抑素的神经内分泌肿瘤患者。
- 采用重抽样程序和相关系数(r)分析177Lu-DOTATATE在有或无既往CRHE患者中的效果。
主要发现
- 有和无CRHE患者的毒性比例相当(P=0.246)。
- 任何毒性均与既往CRHE(r=-0.3至-0.03)或栓塞至首次PRRT的间隔时间(r=-0.59至0.17)无统计学显著相关。
- PRRT后,CRHE患者中76.5%获得获益(部分缓解+疾病稳定),23.4%出现疾病进展。
- 与无CRHE患者相比,CRHE患者PRRT后疾病稳定更多(P=0.048)、疾病进展更少(P=0.046)。
- CRHE与无CRHE状态在PRRT后获得部分缓解/完全缓解的概率相同(P=0.50)。
关键数值与推荐
- 毒性比例比较P=0.246。
- 毒性(任何)与既往CRHE的相关系数r=-0.3至-0.03,与栓塞至首次PRRT间隔时间的相关系数r=-0.59至0.17。
- CRHE患者PRRT后获益(部分缓解+疾病稳定)76.5%,疾病进展23.4%。
- 疾病稳定比较P=0.048,疾病进展比较P=0.046,部分缓解/完全缓解比较P=0.50。
临床怎么用
- 原文结论指出既往CRHE病史不是后续PRRT的禁忌证。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Peptide receptor radionuclide therapy (PRRT) with Lu-DOTATATE is shown to be an effective therapeutic option for somatostatin-expressing neuroendocrine neoplasms. Some concerns are raised over safety of this modality in patients with a history of regional chemoembolization and radionuclide hepatic embolization (CRHE) and is cause of reluctance among some physicians for suggesting Lu-DOTATATE in this patient population. METHODS: We retrospectively reviewed 143 patients with somatostatin-expressing neuroendocrine tumors who underwent Lu-DOTATATE PRRT. Statistical analysis was performed on effect of Lu-DOTATATE in patients with and without prior CRHE using resampling procedures and correlation coefficient (r). RESULTS: Proportion of toxicity in patients with and without CRHE was comparable (P = 0.246). No statistically significant correlation (r) found between any toxicity and prior CRHE (r = -0.3 to -0.03) or time elapsed between embolization and the first cycle of PRRT (r = -0.59 to 0.17). Following PRRT, 76.5% of patients with CRHE experienced benefit (partial response + stable disease), whereas 23.4% experienced progressive disease. Patients with CRHE showed more stable disease (P = 0.048) and less progressive disease (P = 0.046) following PRRT compared with no CRHE. The CRHE and no-CRHE status shared same probability for developing partial response/complete response following PRRT (P = 0.50). CONCLUSIONS: Treatment with Lu-DOTATATE did not show clinically or statistically significant toxicity in CRHE patients regardless of frequency of embolization or time interval between embolization and first PRRT. Results suggested a statistically significant higher response rate in patients with a history of CRHE. A prior history of CRHE is not a contraindication to subsequent PRRT.
引用
- Hamiditabar M, Ali M, Bolek L, et al. Safety and Effectiveness of 177Lu-DOTATATE Peptide Receptor Radionuclide Therapy After Regional Hepatic Embolization in Patients With Somatostatin-Expressing Neuroendocrine Tumors. Clin Nucl Med. 2017. PMID: 28832377. doi:10.1097/RLU.0000000000001818
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。